The National Institutes of Health agreed to pay Kalypsys Inc. up to $30 million over four years for access to the firm's technology, which is expected to help scientists efficiently and simultaneously screen a broad portfolio of biological assays. (BioWorld Today)
The National Institutes of Health agreed to pay Kalypsys Inc. up to $30 million over four years for access to the firm's technology, which is expected to help scientists efficiently and simultaneously screen a broad portfolio of biological assays. (BioWorld Today)
Theratechnologies Inc. expects to initiate a Phase III trial later this year for ThGRF, a candidate for HIV-associated lipodystrophy. At the same time, the Montreal-based company said it intends to restructure its senior management responsibilities and recruit a new chief executive officer. Luc Tanguay, the firm's current president and CEO, will assume the role of senior executive vice president and chief financial officer once a new CEO is named. (BioWorld Today)
